{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.7","upperLimit":"11.1","value":"1.8"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"35.0","value":"1.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"description":"Time to response was defined as the time interval from the date of the first dose of the study drug until the initial observation of CR or PR for participants with confirmed CR/PR. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to \\<10 mm in short axis. CR for non-target lesion: Disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (\\<10mm short axis) and norrmalization of tumor marker level. PR: at least a 30% decrease in the SLD of target lesions, taking as reference the Baseline sum diameters.","dispersionType":"Full Range","groups":[{"description":"Brigatinib 90 mg, tablets, orally, once daily in each Cycle of 28 days until disease progression or intolerable toxicity (median duration of exposure was 402 days).","id":"OG000","title":"Brigatinib 90 mg"},{"description":"Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in Cycle 2 and onward Cycles of 28 days until disease progression or intolerable toxicity (median duration of exposure was 522 days).","id":"OG001","title":"Brigatinib 90 mg - 180 mg"}],"paramType":"MEDIAN","populationDescription":"ITT Population included all participants who were randomized to each regimen regardless of whether they received study drug or adhered to the assigned dose. Participants who had confirmed CR or PR were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to approximately 69 months","title":"Time to Response","type":"SECONDARY","unitOfMeasure":"months"}